FIELD: medicine.
SUBSTANCE: present invention relates to the field of medicine, namely, to a method of treating a subject to prevent cardiovascular disease or reduce the risk of cardiovascular disease, comprising administering to the subject a therapeutically effective amount of 1-methylnicotinamide (1-MHA) or a pharmaceutically acceptable salt thereof, with the subject having a blood C-reactive protein (CRP) level of less than 10 mg/l prior to administration, and the cardiovascular disease is selected from the group consisting of ischemic heart disease (CHD), peripheral artery disease, carotid artery disease, congestive heart failure, stroke, myocardial infarction, angor pectoris, and a combination thereof, while preferably the method reduces the level of CRP in the blood or serum in the subject compared to the level before administration; in this case, preferably the pharmacologically acceptable salt is 1-methylnicotinamide chloride, and preferably the subject is a person.
EFFECT: present invention provides a reduction in the level of C-reactive protein in the blood or blood serum.
7 cl, 2 tbl, 1 ex
